Compare Cadila Healthcare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GSK PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GSK PHARMA CADILA HEALTHCARE/
GSK PHARMA
 
P/E (TTM) x 25.3 53.9 47.0% View Chart
P/BV x 4.4 12.2 36.5% View Chart
Dividend Yield % 0.8 1.3 59.7%  

Financials

 CADILA HEALTHCARE   GSK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
GSK PHARMA
Mar-19
CADILA HEALTHCARE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3523,595 9.8%   
Low Rs2071,253 16.5%   
Sales per share (Unadj.) Rs139.2184.7 75.4%  
Earnings per share (Unadj.) Rs11.826.3 44.7%  
Cash flow per share (Unadj.) Rs18.629.2 63.7%  
Dividends per share (Unadj.) Rs3.5020.00 17.5%  
Dividend yield (eoy) %1.30.8 151.8%  
Book value per share (Unadj.) Rs101.4126.3 80.2%  
Shares outstanding (eoy) m1,023.74169.40 604.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.013.1 15.3%   
Avg P/E ratio x23.792.2 25.8%  
P/CF ratio (eoy) x15.083.1 18.1%  
Price / Book Value ratio x2.819.2 14.4%  
Dividend payout %29.876.1 39.1%   
Avg Mkt Cap Rs m286,033410,626 69.7%   
No. of employees `00013.45.0 270.3%   
Total wages/salary Rs m24,1455,372 449.5%   
Avg. sales/employee Rs Th10,632.76,306.7 168.6%   
Avg. wages/employee Rs Th1,801.21,083.1 166.3%   
Avg. net profit/employee Rs Th898.5898.0 100.1%   
INCOME DATA
Net Sales Rs m142,53131,281 455.6%  
Other income Rs m1,1391,023 111.3%   
Total revenues Rs m143,67032,304 444.7%   
Gross profit Rs m24,1986,009 402.7%  
Depreciation Rs m6,965486 1,433.1%   
Interest Rs m3,4186 56,966.7%   
Profit before tax Rs m14,9546,540 228.7%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3,1982,373 134.8%   
Profit after tax Rs m12,0444,454 270.4%  
Gross profit margin %17.019.2 88.4%  
Effective tax rate %21.436.3 58.9%   
Net profit margin %8.514.2 59.3%  
BALANCE SHEET DATA
Current assets Rs m87,15420,061 434.4%   
Current liabilities Rs m82,69414,543 568.6%   
Net working cap to sales %3.117.6 17.7%  
Current ratio x1.11.4 76.4%  
Inventory Days Days7157 125.8%  
Debtors Days Days9414 667.2%  
Net fixed assets Rs m133,23614,343 928.9%   
Share capital Rs m1,0241,694 60.4%   
"Free" reserves Rs m102,73319,704 521.4%   
Net worth Rs m103,75721,398 484.9%   
Long term debt Rs m32,1462 1,607,300.0%   
Total assets Rs m236,86639,113 605.6%  
Interest coverage x5.41,091.0 0.5%   
Debt to equity ratio x0.30 331,481.0%  
Sales to assets ratio x0.60.8 75.2%   
Return on assets %6.511.4 57.2%  
Return on equity %11.620.8 55.8%  
Return on capital %13.731.9 43.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,752534 9,878.7%   
Fx outflow Rs m14,5047,091 204.5%   
Net fx Rs m38,248-6,557 -583.3%   
CASH FLOW
From Operations Rs m25,0543,994 627.3%  
From Investments Rs m-10,123-1,433 706.2%  
From Financial Activity Rs m-10,942-3,584 305.3%  
Net Cashflow Rs m3,989-1,023 -389.9%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.3 10.2 81.4%  
FIIs % 5.9 23.8 24.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 102,036 43.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT PHARMOVA   SUN PHARMA  IPCA LABS  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 385 points, down 0.8% at 51,059 levels.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 4, 2021 03:30 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS